

Dementia with Lewy Bodies

Clinicopathologic correlations of α -synuclein disease

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Learning objectives

- Define the clinicopathologic DLB phenotype and its relation to Parkinson disease.
- Recognize α -synuclein–containing Lewy bodies and Lewy neurites.
- Explain characteristic distribution, morphology and limitations of correlation.
- Distinguish related neurodegenerative pathologies using the supplied textbook.

DLB in the neurodegenerative-disease framework


Synucleinopathy

Lewy pathology

Dementia phenotype

- DLB belongs to the α -synuclein-associated neurodegenerative disorders.
- Its pathology overlaps the Parkinson disease (PD) spectrum.
- Clinical expression prominently includes cognitive and neuropsychiatric abnormalities.

What does “dementia with Lewy bodies” name?



- The term highlights widespread neuronal Lewy bodies in cortex and brainstem.
- Lewy bodies contain aggregated α -synuclein.
- A clinical diagnosis and a pathologic lesion are related, but not interchangeable.

PD and DLB form a disease spectrum

Parkinson-predominant

- Robbins treats PD and DLB as related expressions of Lewy body disease.
- Both share genetic alterations and α -synuclein molecular conformation.

Dementia-predominant

- The relative prominence and sequence of cognitive versus motor signs differ.

Compare the clinical or pathologic level being described—not merely the names.

Clinical pattern: Three emphasized features

Fluctuation

Visual hallucinations

Frontal signs

- Fluctuating course of cognitive dysfunction.
- Visual hallucinations.
- Prominent frontal signs.

Fluctuating cognition is part of the phenotype

- A fluctuating course is specifically highlighted in the Robbins description.
- A single observation may incompletely characterize the cognitive state.
- Variation over time is relevant to clinical description.

Visual hallucinations are a major clinical clue

- Visual hallucinations are named among the characteristic features.
- They accompany a dementing illness rather than defining the lesion by themselves.
- Pathologic identification still depends on the α -synuclein disease context.

“Frontal signs” describe the cognitive profile

- Prominent frontal signs are included clinical description.
- They identify frontal-system dysfunction at the bedside.
- The cited source does not specify a formal executive-test threshold.

The motor–cognitive axis is not fixed

Motor symptoms first


- Some patients have a motor-first PD phenotype before dementia.
- In others dementia is the initial symptom, with motor findings later.

Dementia first

- Thus a uniform sequence cannot describe the whole spectrum.


Compare the clinical or pathologic level being described—not merely the names.

Motor-first trajectory



- An established PD syndrome can later include cognitive impairment.
- The textbook proposes subsequent cortical involvement in some individuals.
- Aggregation “spread” is a suggested mechanism, not a proven individual timeline.

Dementia-first trajectory



- Dementia may occur before recognizably parkinsonian motor symptoms.
- Robbins interprets this as compatible with a different direction of disease involvement.
- Initial presentation does not alone map microscopic propagation.

Two trajectories: One disease family

Motor-first presentation



Cognition later prominent

Dementia-first presentation



Motor signs later emerge


Two documented orders of presentation; Neither establishes a compulsory microscopic route.

A percentage must retain its denominator

Observation $\neq$ general prevalence estimate


- Approximately 10%–15% of individuals with PD develop dementia.
- The reported proportion relates to people with PD description.
- It is NOT an estimate of DLB prevalence in the community.

Dementia in PD can have mixed pathology




- Some people with dementia also have Alzheimer pathologic changes.
- Other degenerative diseases are less frequent concurrent explanations.
- The dominant histologic correlate varies among affected individuals.

Normal α -synuclein: The starting point



- α -Synuclein is an abundant lipid-binding protein normally localized to synapses.
- The SNCA gene encodes α -synuclein.
- Disease is associated with abnormal aggregation rather than mere protein presence.

Why protein aggregation matters



- Lewy bodies are formed from aggregated α -synuclein.
- The adjacent PD section suggests small oligomeric aggregates may be particularly toxic.
- The exact link from cortical inclusions to dementia remains unclear.

Lewy bodies versus Lewy neurites

Neuronal soma


- Lewy bodies are intraneuronal cytoplasmic inclusions.
- Lewy neurites are abnormal neuronal processes containing aggregated α -synuclein.

Neuronal process

- Both lesions contribute to the recognizable synucleinopathy pattern.


Compare the clinical or pathologic level being described—not merely the names.

Anatomic distribution of Lewy pathology




- DLB may contain widespread Lewy bodies in cerebral cortex and brainstem.
- The brainstem component overlaps the PD distribution.
- The cortical component is relevant to the dementia presentation.

Proposed ascending aggregate distribution



- The PD parent section describes aggregates from medulla to brainstem, limbic areas and neocortex.
- This is a proposed disease-progression pattern, not a mandatory DLB sequence.
- Anatomic involvement is broader than substantia nigra alone.

Possible neuron-to-neuron transfer



- Aggregated α -synuclein can be released and taken up by another neuron.
- This finding supports a prion-like propagation hypothesis.
- A mechanistic hypothesis should not be presented as a directly observed patient trajectory.

Why “prion-like” requires qualification

- The term describes possible templated propagation of a misfolded protein.
- The PD section uses supporting experimental evidence for inter-neuronal movement.
- The source does not claim that DLB is an infectious prion disease.

A different clinical direction may occur

Motor-first presentation



Cognition later prominent

Dementia-first presentation



Motor signs later emerge

Two documented orders of presentation; Neither establishes a compulsory microscopic route.

Synuclein pathology has multiple compartments


Cell body

Neurite

Glia (MSA)

- Neuronal cell bodies contain Lewy bodies.
- Neuronal processes contain Lewy neurites.
- The source also distinguishes the oligodendroglial α -synuclein inclusions of MSA.

Gross pathology: Substantia nigra depigmentation



- Depigmentation of the substantia nigra is typically present in DLB.
- The PD section attributes pallor to loss of pigmented catecholaminergic neurons.
- This finding reflects degeneration, not a specific measurement of cognitive severity.

Gross pathology: Locus ceruleus changes

- Loss of pigmentation also involves the locus ceruleus.
- This is a brainstem nucleus within the broader Lewy pathology distribution.
- Gross examination therefore may show brainstem findings even when cortical atrophy is limited.

Relatively preserved cerebral cortex

Gross cortex relatively preserved

- The cortical architecture is often relatively preserved on gross inspection.
- This contrasts with the severity of cognitive disturbance in DLB.

Microscopic Lewy pathology

- Cortical synuclein pathology may be present despite limited gross abnormalities.

Compare the clinical or pathologic level being described—not merely the names.

Relatively preserved hippocampus

- The hippocampus is listed among grossly relatively preserved structures.
- Gross preservation does not exclude abnormal protein aggregates.
- Alzheimer-type concomitant pathology remains possible in individual cases.

Relatively preserved amygdala

- The amygdala is another area of relative gross preservation noted by Robbins.
- The comparison concerns gross pathology, not absence of microscopic disease.
- Interpret preserved appearance within the wider proteinopathy context.

Gross pathology does not reveal all lesions

Macroscopic observation


- Brainstem depigmentation is an informative macroscopic clue.
- Relatively preserved cortex, hippocampus and amygdala can coexist with dementia.

Protein-level detection

- Microscopic staining is essential to localize α -synuclein pathology.

Compare the clinical or pathologic level being described—not merely the names.


Lewy body: Routine-light-microscopy profile



Schematic neuronal soma

- The PD parent section describes eosinophilic cytoplasmic inclusions.
- Inclusions can be round to elongated, single or multiple.
- A dense central core and surrounding pale halo may be visible.

The core–halo appearance is a pattern, not a requirement



Schematic neuronal soma

- Classical brainstem Lewy bodies can display dense core and pale halo.
- Cortical Lewy bodies are less morphologically distinctive.
- Absence of a textbook-looking inclusion in a single field is not definitive.

Ultrastructural composition



- At ultrastructural level, Lewy bodies contain fine filaments.
- Filaments are densely packed centrally and looser at the periphery.
- α-Synuclein is a major constituent.

Cortical Lewy bodies may be subtle

Brainstem inclusion


- Cortical inclusions are less distinctive than brainstem Lewy bodies.
- They nevertheless contain predominantly α -synuclein.

Subtle cortical inclusion

- Routine morphology alone may underestimate cortical disease.

Compare the clinical or pathologic level being described—not merely the names.

α -Synuclein immunohistochemistry



- α -synuclein immunostaining as a way to detect lesions.
- Staining reveals neuronal Lewy inclusions and Lewy neurites.
- A positive lesion demonstrates protein pathology; It does not alone prove a unique clinical syndrome.

Lewy neurites expand the observable lesion set

Lewy body

- Lewy neurites are abnormal neuronal processes containing aggregates.
- They may be highlighted by α -synuclein immunohistochemistry.

Lewy neurite

- Counting only conspicuous somatic inclusions misses a component of pathology.

Compare the clinical or pathologic level being described—not merely the names.

The cortical inclusion-burden paradox

Inclusion burden $\neq$ cognitive impairment severity

- Cortical Lewy body burden is usually low.
- Cognitive impairment can nevertheless be pronounced.
- A simple inclusion count may fail to explain clinical severity.

Do not overstate the mechanism of dementia

- The precise mechanism of cognitive disturbance is not established in the source.
- Aggregation, neuroanatomic spread and mixed pathology are plausible contexts.
- Avoid presenting a single causal pathway as definitively explaining cognition.

Clinical motor syndrome in the parent PD section


Bradykinesia

Rigidity

Tremor


- PD causes a hypokinetic motor disorder involving the nigrostriatal system.
- Key motor manifestations include bradykinesia, rigidity and tremor.
- The motor phenotype may eventually coexist with dementia.

Nigrostriatal mechanism connects anatomy to movement




- Degeneration of substantia nigra dopaminergic neurons reduces striatal dopamine.
- This deficit contributes to the characteristic motor syndrome.
- The same brainstem pathology may appear in the DLB spectrum.

Symptomatic dopamine replacement: A limitation




- The PD section explains why L-DOPA can improve motor symptoms.
- Dopamine replacement does not stop disease progression.
- Symptomatic motor response is not an assay of cortical Lewy body burden.

SNCA illustrates a primary aggregation mechanism




- SNCA encodes α-synuclein.
- Rare point mutations or increased gene dosage can cause inherited PD.
- The genetic findings connect protein dysregulation to Lewy pathology.

Mitochondrial quality control: PINK1–Parkin




- PINK1 identifies dysfunctional mitochondria and activates Parkin recruitment/signaling.
- Parkin-mediated ubiquitination marks mitochondrial proteins for mitophagy.
- Mutations disrupting this pathway support mitochondrial dysfunction in PD pathogenesis.

Lysosomal biology: GBA1 context



- GBA1 encodes glucocerebrosidase, a lysosomal enzyme.
- Heterozygous pathogenic variants increase PD risk in the source discussion.
- This supports lysosomal–autophagic dysfunction as a mechanism related to protein clearance.

LRRK2 biology is not fully resolved



- Certain LRRK2 variants increase kinase activity and cause PD.
- The parent section implicates abnormal phosphorylation of Rab proteins.
- The causal bridge to α -synuclein accumulation remains uncertain.

Why parent PD mechanisms matter to DLB

Shared genetic context

Shared fold

Different phenotype

- PD and DLB share many genetic alterations.
- They also have the same α -synuclein molecular fold.
- Specific gene-by-gene DLB risk estimates are not provided in the supplied DLB passage.

Alzheimer disease is a key pathologic comparator

Alzheimer: A β + tau

- Alzheimer disease is associated with amyloid- β plaques and tau neurofibrillary tangles.
- DLB is distinguished by neuronal α -synuclein inclusions.

DLB: α -synuclein

- The two processes can coexist rather than being mutually exclusive.

Compare the clinical or pathologic level being described—not merely the names.

Frontotemporal degenerations: Different proteins

FTLD: Tau / TDP-43

- FTLD categories include tau-associated and TDP-43-associated disorders.
- These molecular lesions differ from predominant α -synuclein Lewy pathology.

DLB: α -synuclein

- Dementia phenotype alone cannot specify the aggregated protein.

Compare the clinical or pathologic level being described—not merely the names.

Multiple system atrophy: Same protein, different cell

PD / DLB: Neurons

- MSA is another α -synucleinopathy.
- Its defining inclusions are predominantly cytoplasmic aggregates in oligodendrocytes.

MSA: Oligodendrocytes

- The cellular compartment contrasts with neuronal Lewy inclusions in PD/DLB.

Compare the clinical or pathologic level being described—not merely the names.

Distinct α -synuclein molecular conformations

PD fold

DLB fold: Shared with PD

MSA fold: Distinct

- A shared α -synuclein molecular fold in PD and DLB.
- That fold differs from the α -synuclein fold in MSA.
- Therefore protein identity alone does not capture the whole proteinopathy distinction.

Diagnostic pathology: Identify protein and compartment

Lesion / phenotype	Predominant compartment	Interpretation
Lewy bodies / neurites	Neuronal	PD/DLB spectrum
Glial α -synuclein	Oligodendrocytes	MSA
A β plaques; Tau tangles	Extracellular / neuronal	Alzheimer pathology

Clinicopathologic comparison: Three phenotypes

Disorder	Clinical emphasis	Pathologic context
Parkinson disease	Motor-predominant	Nigrostriatal degeneration
Dementia with Lewy bodies	Cognitive + behavioral	Cortical + brainstem Lewy bodies
Multiple system atrophy	Motor + ataxia + autonomic	Oligodendroglial inclusions

Pathology exercise: A pigmented nucleus becomes pale

- Observation: The substantia nigra is visibly depigmented.
- Interpretation: Loss of pigmented catecholaminergic neurons is implicated.
- Next question: Which protein inclusion supports Lewy-spectrum pathology?

Discussion prompt — interpret observations without inventing additional data

Case exercise: Motor symptoms predate dementia

- Vignette: Longstanding hypokinetic parkinsonism, followed by cognitive decline.
- The motor-first course is compatible with the PD–DLB spectrum.
- Discuss why Alzheimer-type copathology remains possible.

Discussion prompt — interpret observations without inventing additional data

Case exercise: Dementia precedes motor signs

- Vignette: Fluctuating dementia with visual hallucinations; Motor signs emerge later.
- The order resembles the dementia-first phenotype in the source.
- Would this temporal order alone establish an anatomic propagation route?

Discussion prompt — interpret observations without inventing additional data

Case exercise: Cortical Lewy body count is low

- Vignette: Pronounced dementia, relatively preserved cortex and few cortical Lewy bodies.
- The mismatch is consistent with the source description.
- Explain why a low inclusion count does not invalidate clinical disease.

Discussion prompt — interpret observations without inventing additional data

Case exercise: Neuronal versus glial inclusions

- Specimen A: Neuronal α -synuclein Lewy bodies and Lewy neurites.
- Specimen B: Oligodendroglial cytoplasmic α -synuclein inclusions.
- Explain which pattern aligns with PD/DLB and which with MSA.

Discussion prompt — interpret observations without inventing additional data

Integrated synthesis: Four defensible statements

- PD and DLB belong to a related α -synuclein disease spectrum.
- Cortical and brainstem neuronal Lewy pathology characterizes DLB.
- The clinical sequence of dementia and motor signs varies.
- The mechanism linking low cortical inclusion burden to severe dysfunction remains incompletely understood.

Integrated synthesis: Morphology and interpretation

- Look for substantia nigra and locus ceruleus depigmentation.
- Expect relative gross preservation of cortex, hippocampus and amygdala.
- Recognize inclusions and neurites with α -synuclein staining.
- Distinguish protein identity, cellular localization and possible copathology.

Textbook sources and scope

- Primary source: Robbins, Cotran & Kumar, Pathologic Basis of Disease, 11th ed. (2026).
- DLB section: Chapter 28, pp. 1168–1169.
- Supporting parent context: Parkinson disease, pp. 1166–1168; Alzheimer disease and MSA/FTLD sections.
- The source excerpt does not provide formal DLB diagnostic criteria or management recommendations.